Clinical Trials Logo

Alzheimer Disease, Late Onset clinical trials

View clinical trials related to Alzheimer Disease, Late Onset.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06448403 Not yet recruiting - Dementia Clinical Trials

Multimodal Assesment of Alzheimer Patients

MultiAD
Start date: July 1, 2024
Phase:
Study type: Observational [Patient Registry]

The goal of this study is to learn more about the changes in the brains of patients with cognitive impairment (MCI) and Alzheimer's Disease (AD). The main questions the study aims to answer are: 1. What findings can be used to earlier detect patients that will develop Alzheimers? 2. Which differences are seen between healthy and cognitively impaired patients? 3. Which differences are seen between patients with Alzheimers disease? Participants will undergo: - Cognitive tests - Magnetic resonance imaging (MRI) - Electroencephalography (EEG) - Blood sample collection - Fecal sample collection - A randomized group will undergo polysomnography analysis.

NCT ID: NCT05183516 Not yet recruiting - Clinical trials for Alzheimer Disease, Late Onset

Tdap and Biomarkers of Alzheimer's Disease

Start date: May 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

Recently, the Tdap (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis) vaccination was added to the list of immunizations associated with lower incidence of dementia. Plasma-based biomarkers for AD are a welcome alternative to expensive and invasive testing for Alzheimer's; these biomarkers include assessment of amyloid and tau and neurofilament light protein that assesses non-specific neurodegeneration. The investigators will test for these biomarkers, as well as some immune parameters, administer Tdap then repeat the blood tests in six months.